“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...

For the better part of a year, Merck & Co. and Halozyme have been locked in an intellectual property disagreement over the the pharma giant's new, under-the-skin version of cancer megablockbuster ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but the strategy behind the ...

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following product: All healthcare professionals and the general public are ...

New car financing is available for under 4% APR for borrowers with high credit scores Written By Written by Staff Senior Editor, Buy Side Miranda Marquit is a staff senior personal finance editor for ...